GENE ONLINE|News &
Opinion
Blog

2021-09-16| Asia-PacificCOVID-19

Sinovac to Supply Additional 101,000 COVID-19 Vaccine Doses to Singapore

by Kathy Huang
Share To

On September 15, China’s COVID-19 vaccine producer Sinovac announced it will provide Singapore residents with an additional 101,000 doses of its inactivated COVID-19 vaccine CoronaVac. The vaccines will arrive in Singapore on September 20. 

People can receive the shots at private healthcare institutions. One of them, Livingstone Health group, offers an alternative option for those who cannot receive inactivated vaccines under the National Vaccine Programme.

 

Previous Purchase Plan of Sinovac’s COVID-19 Vaccines

In June, Singapore’s Ministry of Health (MOH) authorized private healthcare institutions to purchase Singapore’s unregistered vaccines under the Special Access Route. Sinovac’s CoronaVac is one of the options on the list, not long after it got WHO’s approval for emergency use on June 1. 

So far, only mRNA vaccines developed by Moderna and Pfizer-BioNTech are under Singapore’s national vaccination program. 

To prevent a drought of stock after second doses and boosters, the MOH has purchased 200,000 Sinovac doses. Of that lot, 170,000 shots are available to the public through private care clinics under the Special Access Route framework. 

“This second delivery of 101,000 CoronaVac doses to Singapore reflects the close working relationships that we have established with essential stakeholders in the country,” said Liu Peicheng, spokesperson for Sinovac. We will continue to pursue such strategic collaborations to help countries move to post-pandemic recovery as soon as possible.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
AstraZeneca Welcomes Neurofibromatosis And Asthma Treatment Approvals in Japan
2022-09-28
LATEST
AstraZeneca Welcomes Neurofibromatosis And Asthma Treatment Approvals in Japan
2022-09-28
Biogen Concludes $900 Million Settlement Before Posting Positive Data From Alzheimer’s Trial
2022-09-28
Arsenal Biosciences Announced Another $70 million Collaboration, This Time With Genentech
2022-09-27
Sciwind Biosciences And SynerK Join Forces To Develop siRNA Therapeutics
2022-09-27
Acticor Enrolls First Patient in Phase 2/3 Stroke Treatment Study
2022-09-27
Daiichi Sankyo Wins Approval For Cancer Treatment in Japan
2022-09-26
Seagen Strikes Potential $650 million Deal with LAVA Therapeutics for Cancer Treatment
2022-09-26
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!